α2C-adrenoceptor blockade by clozapine and other antipsychotic drugs

European Journal of Pharmacology

Volumn 462, Issue 1-3, 2003, Pages 33-40

  Kalkman, Hans O ^a   Loetscher, Erika ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antipsychotic; Clozapine; Cognitive function; Functional affinity; Iloperidone; 2 Adrenoceptor antagonist

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; BRIMONIDINE; CHLORPROMAZINE; CLOZAPINE; CYCLIC AMP; HALOPERIDOL; IDAZOXAN; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RECOMBINANT PROTEIN; YOHIMBINE; ZIPRASIDONE; ADRENERGIC RECEPTOR ALPHA(2C); ALPHA 2 ADRENERGIC RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE D2L RECEPTOR; DRUG DERIVATIVE; ISOXAZOLE DERIVATIVE; NORADRENALIN; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PIRENZEPINE; QUINOLONE DERIVATIVE; QUINOXALINE DERIVATIVE; RECEPTOR, ADRENERGIC, ALPHA 2A; RECEPTOR, ADRENERGIC, ALPHA-2A; RISPERIDONE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL LINE; COGNITION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LUMINESCENCE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHO CELL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; PHYSIOLOGY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; CHO CELLS; CLOZAPINE; CRICETINAE; CYCLIC AMP; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HALOPERIDOL; HUMANS; ISOXAZOLES; NOREPINEPHRINE; PIPERAZINES; PIPERIDINES; PIRENZEPINE; QUINOLONES; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; RISPERIDONE; THIAZOLES; TRANSFECTION; YOHIMBINE;

EID: 0037458590     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01308-6     Document Type: Article

References (48)

1. 2-noradrenergic mechanisms to prefrontal cortical function. Arch. Gen. Psychiatry. 53:1996;448-455.
2. Birnbaum S.G., Podell D.M., Arnsten A.F. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol. Biochem. Behav. 67:2000;397-403.
3. Björklund M., Sirviö J., Sallinen J., Scheinin M., Kobilka B.K., Riekkinen P. Alpha2C-Adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns. Neuroscience. 88:1999;1187-1198.
4. Breier A., Buchanan R.W., Waltrip R.W. II, Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology. 10:1994;1-7.
5. Bürki H.R., Ruch W., Asper H., Baggiolini M., Stille G. Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur. J. Pharmacol. 27:1974;180-190.
6. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R. Jr., Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46:1994;121-136.
7. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;2745-2752.
8. 2-noradrenergic system. Effects on cognition. Drugs Aging. 5:1994;116-126.
9. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
10. s. J. Biol. Chem. 267:1992;15795-15801.
11. s. Mol. Pharmacol. 45:1994;696-702.
12. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 20:1999;29-34.
13. Fraser C.M., Arakawa S., McCombie W.R., Venter J.C. Cloning, sequence analysis, and permanent expression of a human alpha2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J. Biol. Chem. 264:1989;11754-11761.
14. Friedman J.I., Temporini H., Davis K.L. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry. 45:1999;1-16.
15. Furchgott R.F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. Blaschko H., Muscholl E. Handbook of Experimental Pharmacology. Catecholamines. vol. 33:1972;283-335 Springer-Verlag, Berlin.
16. Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 24:2000;1329-1338.
17. 2-adrenoceptor antagonist, atipamezole. Eur. J. Pharmacol. 347:1998;29-40.
18. Jäkälä P., Riekkinen M., Sirviö J., Koivisto E., Kejonen K., Vanhanen M., Riekkinen P. Jr. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 20:1999;460-470.
19. 2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem. Pharmacol. 55:1998;1035-1043.
20. Kalkman H.O., Subramanian N., Hoyer D. Extended radioligand binding profile of iloperidone. A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 25:2001;904-914.
21. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
22. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
23. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157:2000;514-520.
24. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25:1999;201-222.
25. King D.J. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr. Scand., Suppl. 380:1994;53-58.
26. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20:1999;612-627.
27. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37:1999;1-11.
28. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35:1999;51-68.
29. Li B.M., Mao Z.M., Wang M., Mei Z.T. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology. 21:1999;601-610.
30. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry. 168:1996;571-579.
31. 2-adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats. Psychopharmacology. 155:2001;379-388.
32. McMillen B.A., Shore P.A. Comparative effects of clozapine and α-adrenoceptor blocking drugs on regional noradrenaline metabolism in rat brain. Eur. J. Pharmacol. 52:1978;225-230.
33. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
34. Middleton H.C., Sharma A., Agouzoul D., Sahakian B.J., Robbins T.W. Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine. Psychopharmacology. 145:1999;401-411.
35. 35S]GTPγS binding study. Eur. J. Pharmacol. 355:1998;245-256.
36. Nordström A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 33:1993;227-235.
37. Olianas M., Maullu C., Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology. 20:1999;263-270.
38. Pickar D., Owen R.R., Litman R.E., Konicki P.E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. Psychiatry. 49:1992;345-353.
39. Purdon S.E., Labelle A., Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr. Res. 48:2001;57-67.
40. 2-adrenergic antagonist during an oculomotor delayed-response task. J. Neurophysiol. 80:1998;2200-2205.
41. 2-adrenergic receptor subtype gene expression in rat brain. Brain Res. Mol. Brain Res. 21:1994;133-149.
42. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.). 124:1996;57-73.
43. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
44. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br. J. Psychiatr., Suppl. 38:1999;44-51.
45. Sokoloff P., Schwartz J.C. Novel dopamine receptors half a decade later. Trends Pharmacol. Sci. 16:1995;270-275.
46. Starke K., Göthert M., Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 69:1989;864-989.
47. Szewczak M.R., Corbett R., Rush D.K., Wilmot C.A., Conway P.G., Strupczewski J.T., Cornfeldt M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 274:1995;1404-1413.
48. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321:1997;349-354.